Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 331 clinical trials
Surgery for Recurrent Glioblastoma (RESURGE)

Patients with glioblastoma face a grim prognosis. Despite recent advancement in neurosurgical technology and neuro-oncology glioblastomas almost invariably progress or recur after a median of 4

MRI
recurrent glioblastoma
tumour resection
temozolomide
  • 145 views
  • 27 May, 2022
  • 23 locations
Supramarginal Resection in Patients With Glioblastoma: A Randomised Controlled Trial

Gliomas are the most common malignant brain tumor. Glioblastoma, WHO grade IV astrocytoma, is the most common subtype and unfortunately also the most aggressive subtype with median survival in

gross total resection
karnofsky performance status
complete resection
malignant brain tumor
malignant glioma
  • 0 views
  • 22 Oct, 2022
  • 18 locations
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (GBM AGILE)

Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate

karnofsky performance status
recurrent glioblastoma
lomustine
recurrent disease
gliosarcoma
  • 107 views
  • 07 Oct, 2022
  • 3 locations
Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma

(Phase 1) and isocitrate dehydrogenase (IDH) wild type recurrent glioblastoma (glioblastoma expansion cohort in Phase 1 and Phase 2).

recurrent disease
IDH2
MRI
astrocytoma
measurable disease
  • 0 views
  • 05 Apr, 2022
  • 4 locations
A Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Radiotherapy With or Without Temozolomide and in Recurrent Glioblastoma as Single Agent

This study aims to establish the recommended dose of [177Lu]Lu-DOTA-TATE in combination with the standard of care or as single agent in three different groups of participants with Glioblastoma

MRI
recurrent glioblastoma
recurrent disease
temozolomide
  • 0 views
  • 11 Oct, 2022
  • 6 locations
A Randomized, Double-blind, Placebo-controlled Adjuvant Trial in Newly Diagnosed Primary Glioblastoma Subjects to Assess the Efficacy and Safety of 2-hydroxyoleic Acid (2-OHOA) in Combination With Radiotherapy and Temozolomide Standard of Care Treatment. (CLINGLIO)

The proposed Phase IIB/III randomized, double-blind, placebo-controlled trial in subjects with newly diagnosed primary glioblastoma multiforme (ndGBM) aims to compare the efficacy and safety of

renal function test
malignant glioma
tamoxifen
neutrophil count
temozolomide
  • 30 views
  • 28 Oct, 2022
  • 16 locations
An Open-label, Multicenter, Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of RO7428731 in Participants With Glioblastoma Expressing Mutant Epidermal Growth Factor Receptor Variant III

monotherapy in participants with newly diagnosed or recurrent epidermal growth factor receptor variant III (EGFRvIII)-positive glioblastoma (GBM).

karnofsky performance status
temozolomide
  • 0 views
  • 21 Oct, 2022
  • 6 locations
A Phase 1b, Open-label, Dose-Finding Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Subjects With Newly Diagnosed Glioblastoma

diagnosed WHO Grade IV glioblastoma (ndGBM).

karnofsky performance status
MRI
tumour resection
platelet count
neutrophil count
  • 0 views
  • 25 Oct, 2022
  • 30 locations
EF-32: Pivotal, Randomized, Open-Label Study of Optune® (Tumor Treating Fields, 200kHz) Concomitant With Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma (EF-32)

To test the effectiveness and safety of Optune® given concomitantly with radiation therapy (RT) and temozolomide (TMZ) in newly diagnosed GBM patients, compared to radiation therapy and

gross total resection
karnofsky performance status
complete resection
tumor treating fields therapy
tumor progression
  • 72 views
  • 29 Oct, 2022
  • 101 locations
  • 0 views
  • 17 Dec, 2021
  • 14 locations